KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy
Cancers · 25.02.2025 · 17 (5) · 785
DOI: 10.3390/cancers17050785 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 25.02.2025. Verfasst von Priyanka Uniyal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Technology, School of Health Sciences and Technology, UPES, Dehradun 248007, India. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 192 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The Kirsten rat sarcoma viral oncogene homologue (KRAS) mutation is one of the most prevailing mutations in various tumors and is difficult to cure. Long-term proliferation in carcinogenesis is primarily initiated by oncogenic KRAS-downstream signaling. Recent research suggests that it also activates the autocrine effect and interplays the tumor microenvironment (TME). Here, we discuss the emerging research, including KRAS mutations to immune evasion in TME, which induce immunological modulation that promotes tumor development. This review gives an overview of the existing knowledge of the underlying connection between KRAS mutations and tumor immune modulation. It also addresses the mechanisms to reduce the effect of oncogenes on the immune system and recent advances in clinical trials for immunotherapy in KRAS-mutated cancers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Technology, School of Health Sciences and Technology, UPES, Dehradun 248007, India.
- Division of Cancer Immunology and Microbiology, Medicine, and Oncology Integrated Service Unit, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
- South Texas Center of Excellence in Cancer Research (ST-CECR), School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
- Amity School of Pharmaceutical Sciences, Amity University, Mohali 140306, India.
- Division of Hematology & Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
ORCID-Profile: Deepak Parashar, Ravi Rawat
Zitieren
APA
Uniyal, P., Kashyap, V. K., Behl, T., Parashar, D., & Rawat, R. (2025). KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy. Cancers, 17(5), 785. https://doi.org/10.3390/cancers17050785
Vancouver
Uniyal P, Kashyap VK, Behl T, Parashar D, Rawat R. KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy. Cancers. 2025;17(5):785. doi:10.3390/cancers17050785
BibTeX
@article{Uniyal2025,
author = {Uniyal, Priyanka and Kashyap, Vivek Kumar and Behl, Tapan and Parashar, Deepak and Rawat, Ravi},
title = {KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy},
journal = {Cancers},
year = {2025},
volume = {17},
number = {5},
pages = {785},
doi = {10.3390/cancers17050785}
}
EUVIMED